- $136.04m
- $29.19m
- $33.03m
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Grant of Options, RSUs and PSUs and PDMR Dealing
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
Brief: Maxcyte Sees 2025 Core Revenue To Grow 8% To 15%
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Q4 & FY 2024 Financial Results
MaxCyte Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: MaxCyte Q4 Revenue USD 8.7 Million Vs. IBES Estimate USD 7.93 Million
MaxCyte Inc expected to post a loss of 12 cents a share - Earnings Preview
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
Brief: Maxcyte Says Enters Strategic Platform License With TG Therapeutics
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Strategic Platform License with TG Therapeutics
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Notice of Results
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Exercise of options and PDMR dealing
Brief: Maxcyte Buys Sequre Dx For $4.5 Million
MaxCyte, Inc. MaxCyte, Inc. - MXCR - MaxCyte® Acquires SeQure Dx
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company
MaxCyte, Inc. MaxCyte, Inc. - MXCR - Holding(s) in Company